<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205150</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066X2204</org_study_id>
    <secondary_id>2017-002046-71</secondary_id>
    <nct_id>NCT03205150</nct_id>
  </id_info>
  <brief_title>Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients</brief_title>
  <official_title>A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of LIK066 on a variety of metabolic and
      inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Alanine aminotransferase (ALT) at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on ALT after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Aspartate aminotransferase (AST) at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on AST after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent liver fat at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on intrahepatic lipid after 12 weeks of treatment as measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total body weight at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on total body weight after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on non-invasive liver fibrosis markers (Enhanced Liver Fibrosis (ELF) panel) at week 12</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on non-invasive markers of liver fibrosis after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Observed maximum time duration of maximum concentration (Tmax) following drug administration</measure>
    <time_frame>Day 56 (0, 1,2, 4 and 6 hrs post dose)</time_frame>
    <description>To evaluate Tmax of LIK066 in NASH patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Observed area under the curve up to the last measurable concentration (AUClast) following drug administration</measure>
    <time_frame>Day 56 (0, 1,2, 4 and 6 hrs post dose)</time_frame>
    <description>To evaluate AUClast of LIK066 in NASH patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Observed maximum plasma concentration (Cmax) following drug administration</measure>
    <time_frame>Day 56 (0, 1,2, 4 and 6 hrs post dose)</time_frame>
    <description>To evaluate Cmax of LIK066 in NASH patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body mass index (BMI) at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on BMI after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist and hip (WTH) ratio at week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To determine the effect of LIK066 on waist and hip (WTH) ratio after 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Obese Patients With Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>LIK066 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 Dose 1 will be taken once daily before lunch for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 Dose 2 will be taken once daily before lunch for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo will be taken once daily before lunch for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 tablets will be taken orally once daily</description>
    <arm_group_label>LIK066 Dose 1</arm_group_label>
    <arm_group_label>LIK066 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets will be taken orally once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        EITHER

        -Histologic confirmed NASH based on liver biopsy obtained 2 years or less before
        randomization with a fibrosis level of F1, F2 or F3 in the absence of a histological
        diagnosis of alternative chronic liver disease AND ALT greater than or equal to 50 IU/L
        (males) or greater than or equal to 35 IU/L (females) at screening.

        OR

        Phenotypic diagnosis of NASH based on presence of ALL three of the following at screening:

          -  ALT greater than or equal to 50IU/L (males) or greater than or equal to 35 IU/L
             (females) AND

          -  BMI greater than or equal to 27 kg/m^2 (in patients with a self-identified race other
             than Asian) or greater than or equal to 23 kg/m^2 (in patients with a self identified
             Asian race) AND

          -  Diagnosis of Type 2 diabetes mellitus by HbA1c: greater than or equal to 6.5 % and
             less than or equal to 10%

          -  Patients must weigh no more than 150 kg (330 lbs) to participate in the study.

          -  Male and female patients 18 years or older at the time of screening visit.

        Exclusion Criteria:

          -  History or presence of other concomitant liver diseases

          -  History or current diagnosis of ECG abnormalities

          -  Use of GLP-1 agonists, SGLT2 inhibitors, TZDs, FXR agonists and any pharmacologically
             active weight loss drugs within 6 weeks of screening and until end of study

          -  Patients with contraindications to MRI imaging

          -  Current or history of significant alcohol consumption

          -  Clinical evidence of hepatic decompensation or severe liver impairment

          -  Women of child bearing potential (unless on basic contraception methods)

          -  Presence of liver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>343621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chia-Yi</city>
        <zip>60002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Obese</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>non-alcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

